Yo-El Ju

information about patients so that we could help direct them to more confirmatory testing or treatment if the diagnostic accuracy is good.

So one of the main projects I've been working on for the past few years, which I hope to finish up soon, is developing markers that we can pull out from the brainwaves, the EEG,

so that we can hopefully identify who has preclinical Alzheimer's disease.

You know, this is all, you know, non-invasive data that we collect during a sleep study that's otherwise kind of discarded and never used again.

So if we can actually narrow down the

the pool of people that we'd want to follow up with testing with a plasma biomarker or imaging, I think that would be great, especially, you know, now that we have the biomarker field has developed so much in Alzheimer's disease.

I think that we need to kind of

think more about, well, how are we going to bring this to the masses?

We can't have 100% of people getting their plasma AD biomarkers tested.

We need to be able to narrow the pool more to use our resources efficiently.

Okay.

If I had a one-size-fits-all solution, then I would be a rich woman.

So, you know, as people go through perimenopause and then menopause, sleep issues become much more prevalent.

So I don't want to...

overbear on sleep apnea, but that is actually a big part of it.

So women have about half the prevalence of men in terms of sleep apnea before menopause.

After menopause, they've caught up.

And so this means that around menopause is when a lot of people, a lot of women,

develop and are diagnosed with sleep apnea.

So I think that is actually a big chunk of it that we don't talk about very much.